2025-07-012026-02-282026-02-28false13221802YEWMAKER MEDICINES LTD2026-06-17falseiso4217:GBPxbrli:pure132218022025-06-30132218022026-02-28132218022025-07-012026-02-28132218022024-06-30132218022025-06-30132218022024-07-012025-06-3013221802bus:SmallEntities2025-07-012026-02-2813221802bus:AuditExempt-NoAccountantsReport2025-07-012026-02-2813221802bus:AbridgedAccounts2025-07-012026-02-2813221802bus:PrivateLimitedCompanyLtd2025-07-012026-02-2813221802core:WithinOneYear2026-02-2813221802core:AfterOneYear2026-02-2813221802core:WithinOneYear2025-06-3013221802core:AfterOneYear2025-06-3013221802core:ShareCapital2026-02-2813221802core:SharePremium2026-02-2813221802core:RevaluationReserve2026-02-2813221802core:OtherReservesSubtotal2026-02-2813221802core:RetainedEarningsAccumulatedLosses2026-02-2813221802core:ShareCapital2025-06-3013221802core:SharePremium2025-06-3013221802core:RevaluationReserve2025-06-3013221802core:OtherReservesSubtotal2025-06-3013221802core:RetainedEarningsAccumulatedLosses2025-06-3013221802core:LandBuildings2026-02-2813221802core:PlantMachinery2026-02-2813221802core:Vehicles2026-02-2813221802core:FurnitureFittings2026-02-2813221802core:OfficeEquipment2026-02-2813221802core:NetGoodwill2026-02-2813221802core:IntangibleAssetsOtherThanGoodwill2026-02-2813221802core:ListedExchangeTraded2026-02-2813221802core:UnlistedNon-exchangeTraded2026-02-2813221802core:LandBuildings2025-06-3013221802core:PlantMachinery2025-06-3013221802core:Vehicles2025-06-3013221802core:FurnitureFittings2025-06-3013221802core:OfficeEquipment2025-06-3013221802core:NetGoodwill2025-06-3013221802core:IntangibleAssetsOtherThanGoodwill2025-06-3013221802core:ListedExchangeTraded2025-06-3013221802core:UnlistedNon-exchangeTraded2025-06-3013221802core:LandBuildings2025-07-012026-02-2813221802core:PlantMachinery2025-07-012026-02-2813221802core:Vehicles2025-07-012026-02-2813221802core:FurnitureFittings2025-07-012026-02-2813221802core:OfficeEquipment2025-07-012026-02-2813221802core:NetGoodwill2025-07-012026-02-2813221802core:IntangibleAssetsOtherThanGoodwill2025-07-012026-02-2813221802core:ListedExchangeTraded2025-07-012026-02-2813221802core:UnlistedNon-exchangeTraded2025-07-012026-02-2813221802core:MoreThanFiveYears2025-07-012026-02-2813221802core:Non-currentFinancialInstruments2026-02-2813221802core:Non-currentFinancialInstruments2025-06-3013221802dpl:CostSales2025-07-012026-02-2813221802dpl:DistributionCosts2025-07-012026-02-2813221802core:LandBuildings2025-07-012026-02-2813221802core:PlantMachinery2025-07-012026-02-2813221802core:Vehicles2025-07-012026-02-2813221802core:FurnitureFittings2025-07-012026-02-2813221802core:OfficeEquipment2025-07-012026-02-2813221802dpl:AdministrativeExpenses2025-07-012026-02-2813221802core:NetGoodwill2025-07-012026-02-2813221802core:IntangibleAssetsOtherThanGoodwill2025-07-012026-02-2813221802dpl:GroupUndertakings2025-07-012026-02-2813221802dpl:ParticipatingInterests2025-07-012026-02-2813221802dpl:GroupUndertakingscore:ListedExchangeTraded2025-07-012026-02-2813221802core:ListedExchangeTraded2025-07-012026-02-2813221802dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2025-07-012026-02-2813221802core:UnlistedNon-exchangeTraded2025-07-012026-02-2813221802dpl:CostSales2024-07-012025-06-3013221802dpl:DistributionCosts2024-07-012025-06-3013221802core:LandBuildings2024-07-012025-06-3013221802core:PlantMachinery2024-07-012025-06-3013221802core:Vehicles2024-07-012025-06-3013221802core:FurnitureFittings2024-07-012025-06-3013221802core:OfficeEquipment2024-07-012025-06-3013221802dpl:AdministrativeExpenses2024-07-012025-06-3013221802core:NetGoodwill2024-07-012025-06-3013221802core:IntangibleAssetsOtherThanGoodwill2024-07-012025-06-3013221802dpl:GroupUndertakings2024-07-012025-06-3013221802dpl:ParticipatingInterests2024-07-012025-06-3013221802dpl:GroupUndertakingscore:ListedExchangeTraded2024-07-012025-06-3013221802core:ListedExchangeTraded2024-07-012025-06-3013221802dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-07-012025-06-3013221802core:UnlistedNon-exchangeTraded2024-07-012025-06-3013221802core:NetGoodwill2026-02-2813221802core:IntangibleAssetsOtherThanGoodwill2026-02-2813221802core:LandBuildings2026-02-2813221802core:PlantMachinery2026-02-2813221802core:Vehicles2026-02-2813221802core:FurnitureFittings2026-02-2813221802core:OfficeEquipment2026-02-2813221802core:AfterOneYear2026-02-2813221802core:WithinOneYear2026-02-2813221802core:ListedExchangeTraded2026-02-2813221802core:UnlistedNon-exchangeTraded2026-02-2813221802core:ShareCapital2026-02-2813221802core:SharePremium2026-02-2813221802core:RevaluationReserve2026-02-2813221802core:OtherReservesSubtotal2026-02-2813221802core:RetainedEarningsAccumulatedLosses2026-02-2813221802core:NetGoodwill2025-06-3013221802core:IntangibleAssetsOtherThanGoodwill2025-06-3013221802core:LandBuildings2025-06-3013221802core:PlantMachinery2025-06-3013221802core:Vehicles2025-06-3013221802core:FurnitureFittings2025-06-3013221802core:OfficeEquipment2025-06-3013221802core:AfterOneYear2025-06-3013221802core:WithinOneYear2025-06-3013221802core:ListedExchangeTraded2025-06-3013221802core:UnlistedNon-exchangeTraded2025-06-3013221802core:ShareCapital2025-06-3013221802core:SharePremium2025-06-3013221802core:RevaluationReserve2025-06-3013221802core:OtherReservesSubtotal2025-06-3013221802core:RetainedEarningsAccumulatedLosses2025-06-3013221802core:NetGoodwill2024-06-3013221802core:IntangibleAssetsOtherThanGoodwill2024-06-3013221802core:LandBuildings2024-06-3013221802core:PlantMachinery2024-06-3013221802core:Vehicles2024-06-3013221802core:FurnitureFittings2024-06-3013221802core:OfficeEquipment2024-06-3013221802core:AfterOneYear2024-06-3013221802core:WithinOneYear2024-06-3013221802core:ListedExchangeTraded2024-06-3013221802core:UnlistedNon-exchangeTraded2024-06-3013221802core:ShareCapital2024-06-3013221802core:SharePremium2024-06-3013221802core:RevaluationReserve2024-06-3013221802core:OtherReservesSubtotal2024-06-3013221802core:RetainedEarningsAccumulatedLosses2024-06-3013221802core:AfterOneYear2025-07-012026-02-2813221802core:WithinOneYear2025-07-012026-02-2813221802core:Non-currentFinancialInstrumentscore:CostValuation2025-07-012026-02-2813221802core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-07-012026-02-2813221802core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-07-012026-02-2813221802core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-07-012026-02-2813221802core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-07-012026-02-2813221802core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-07-012026-02-2813221802core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-07-012026-02-2813221802core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-07-012026-02-2813221802core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-07-012026-02-2813221802core:Non-currentFinancialInstrumentscore:CostValuation2026-02-2813221802core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2026-02-2813221802core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2026-02-2813221802core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2026-02-2813221802core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2026-02-2813221802core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2026-02-2813221802core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2026-02-2813221802core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2026-02-2813221802core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2026-02-2813221802core:Non-currentFinancialInstrumentscore:CostValuation2025-06-3013221802core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-06-3013221802core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-06-3013221802core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-06-3013221802core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-06-3013221802core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-06-3013221802core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-06-3013221802core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-06-3013221802core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-06-3013221802bus:Director12025-07-012026-02-28

YEWMAKER MEDICINES LTD

Registered Number
13221802
(England and Wales)

Unaudited Financial Statements for the Period ended
28 February 2026

YEWMAKER MEDICINES LTD
Company Information
for the period from 1 July 2025 to 28 February 2026

Director

Dr Sabera Nazneen Rahman

Registered Address

Unit 3 Upp Hall Farm
Salmons Lane
Colchester
CO6 1RY

Registered Number

13221802 (England and Wales)
YEWMAKER MEDICINES LTD
Balance Sheet as at
28 February 2026

Notes

28 Feb 2026

30 Jun 2025

£

£

£

£

Current assets
Debtors41,132137,500
Cash at bank and on hand-215,502
1,132353,002
Creditors amounts falling due within one year5-(326,184)
Net current assets (liabilities)1,13226,818
Total assets less current liabilities1,13226,818
Net assets1,13226,818
Capital and reserves
Called up share capital1,0001,000
Profit and loss account13225,818
Shareholders' funds1,13226,818
The financial statements were approved and authorised for issue by the Director on 17 June 2026, and are signed on its behalf by:
Dr Sabera Nazneen Rahman
Director
Registered Company No. 13221802
YEWMAKER MEDICINES LTD
Notes to the Financial Statements
for the period ended 28 February 2026

1.Accounting policies
Statement of compliance
The financial statements have been prepared in accordance with the Companies Act 2006 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the financial reporting standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Turnover policy
Turnover comprises the fair value of the consideration received or receivable for the provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts. The company recognises revenue when: The amount of revenue can be reliably measured; it is probable that future economic benefits will flow to the entity; and specific criteria have been met for each of the company's activities.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Current taxation
The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except when it relates to other comprehensive income. The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.
Tangible fixed assets and depreciation
Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses. The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation. Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Straight line (years)
Office Equipment3
Trade and other debtors
Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business. Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.
Cash and cash equivalents
Cash and cash equivalents comprise cash at bank and on hand, demand deposits with banks and other short-term highly liquid investments with original maturities of three months or less. Bank overdrafts are disclosed separately. For the purpose of the cash flow statement, bank overdrafts form an integral part of the company's cash management and are included as a component of cash and cash equivalents.
Trade and other creditors
Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities. Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost.
Share capital
Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new ordinary shares or options are shown in equity as a deduction, net of tax, from the proceeds.
2.Average number of employees

20262025
Average number of employees during the year11
3.Tangible fixed assets

Total

£
Cost or valuation
At 01 July 25966
At 28 February 26966
Depreciation and impairment
At 01 July 25966
At 28 February 26966
Net book value
At 28 February 26-
At 30 June 25-
4.Debtors: amounts due within one year

2026

2025

££
Trade debtors / trade receivables-137,500
Amounts owed by group undertakings1,132-
Total1,132137,500
5.Creditors: amounts due within one year

2026

2025

££
Amounts owed to related parties-159,180
Taxation and social security-8,688
Accrued liabilities and deferred income-158,316
Total-326,184
6.Share capital
The company has issued share capital of 1,000 ordinary shares of £1 each. There has been no change to the share capital in this year.
7.Parent-subsidiary relationships
The company is 100% owned by Yewmaker Ltd. At the year end the company owed £1,131.39 (2025: £(159,179.78)) Yewmaker Ltd